Document Classification

Section Type: METHODS

Text: Patients (treated with CZP plus methotrexate [MTX] or placebo plus MTX) were classified at baseline and at 52 weeks as high, moderate, low activity/severity or remission, according to the DAS28 (> 5. 1, > 3. 2 to 5. 1, 2. 6 to 3. 2, < 2. 6 [total range 0-10]), the CDAI (> 22, > 10 to 22, > 2. 8 to 10, 2. 8 [total range 0-76]), and RAPID3 (> 12, > 6 to 12, > 3 to 6, 3 [total range 0-30]), as well as for good, moderate, and poor EULAR-DAS28 and proposed RAPID3 response criteria.